All News
What is the difference between difficult to treat, and treatment-refractory?
(see these criteria for PsA)
Treatment refractory means that co-morbidities, psychosocial issues and other factors have been managed adequately, but inflammation keeps on going
#EULAR2025 @RheumNow https://t.co/Fzpf0eiCWY
David Liew drdavidliew ( View Tweet)
FMF #Recommendations
#Colchicine can be fatal
🔺️Beware of drug interactions
🔺️Mostly statins in adults
🔺️Macrolides in children
#EULAR2025
@RheumNow https://t.co/SYGLpAJXFu
Nelly ZIADE 🍀 Nellziade ( View Tweet)
Why do we need RA treatment recommendation updates? We keep on getting new data, for our keystone disease
so today Josef Smolen and colleagues present the new 2025 EULAR recommendations
#EULAR2025 @RheumNow https://t.co/OdHL8CAIKv
David Liew drdavidliew ( View Tweet)
67% of HCPs knew of EULAR’s CVD risk guidelines in RMDs—but few could apply them.
✅ Only 13% linked SLE control to CVD risk
🚫 0% picked correct BP/statin use in RA/AS/PsA
Barriers? Time, knowledge, and local guideline gaps.
POS0410-HPR @RheumNow #EULAR2025
Jiha Lee JihaRheum ( View Tweet)
“That is why this task force continues to say: nothing is better than methotrexate and glucocorticoids to start”
- Josef Smolen, on RA treatment
#EULAR2025 @RheumNow https://t.co/AbkgWS8tvH
Links:
David Liew drdavidliew ( View Tweet)
The key changes for the new 2025 EULAR recommendations on RA treatment
#EULAR2025 @RheumNow https://t.co/dp5LnoFdpW
David Liew drdavidliew ( View Tweet)
#EULAR new #RA #recommendations
J Smolen presents justification for
#MTX +#glucocorticoids at onset
do you agree?
Diff from #ACR
#EULAR #Recommendations II
#EULAR2025 @RheumNow https://t.co/wqCX5HA87q
Janet Pope Janetbirdope ( View Tweet)
URAT1 inhibitors look like the way to go in Gout!
Presented in multiple abstracts at #EULAR2025
Pozdeutinurad Ph2 long term safety data chronic gouty arthritis + tophi OP0300
Ph3 RCT of Ruzinurad in hyperuricemia/primary gout OP0302
Ph 2b RCT of SAP-001 Refractory Gout +/-
Aurelie Najm AurelieRheumo ( View Tweet)
EULAR Points to consider for the definition of #D2M #Psoriatic_Arthritis
1️⃣ Failure >= 2 b/tsDMARDs with >=2 different MOA
2️⃣ Perceived as problematic
3️⃣ Evidence of persistent disease (active disease, EMM, inflammation)
#EULAR2025
@RheumNow https://t.co/69nFEYntF0
Nelly ZIADE 🍀 Nellziade ( View Tweet)
EULAR PtC for the definition of #TR (Trt Refractory) #Psoriatic_Arthritis
#D2M
1️⃣ Failure >= 2 b/tsDMARDs
2️⃣ Problematic
3️⃣ Evidence of persistent disease (inflammation is mandatory)
+
4️⃣ Exclude comorbidities, psychosocial factors, failure due to SE/CI
#EULAR2025
@RheumNow https://t.co/8nx26mWX3C
Nelly ZIADE 🍀 Nellziade ( View Tweet)
@RheumNow When it comes to ORAL Surveillance and the 2025 EULAR recommendations, the same sensibility remains.
Appropriate caution based on the RCT, despite observational data, but we’ll see what is yet to come. Plenty to watch this space for
#EULAR2025 @RheumNow https://t.co/fIxHRGDFcK
Links:
David Liew drdavidliew ( View Tweet)
📱 Axia, a digital therapeutic for #axSpa, led to significant improvements in BASDAI, BASFI & ASQoL in a 12-week RCT.
ASAS20: 51% vs 9%; ASAS40: 23% vs 3%.
Promising app-based intervention comprising individualised exercise, pt education & disease Mx.
@RheumNow #EULAR2025 #LB0002
Mrinalini Dey DrMiniDey ( View Tweet)
#EULAR2025 @eular_org update
#Recommendations #Rheumatoid #Rx
prof Smolen
subtle diff between former guidelines
MTX+GC
👇
D/C GCs rapidly
👇
If inadequate response
👇
Other csDMARDs are OUT ❎
✅go to bDMARD or tsDMARD*
TsDMARD after safety assessed
@RheumNow RecommendatnII https://t.co/yUrLdk6Eg1
Janet Pope Janetbirdope ( View Tweet)
#EULAR2025 Abstr#LB0002 Crossover RCT of use of AXIA - a novel app-based intervention showed improvement in disease activity, functionality & quality of life in pople with Axial #SpA vs usual care. Available in Austria currently - awaiting rollout and in other languages @RheumNow https://t.co/nV4QifyikL
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#RA #recommendations #update
Some recommendations were merged
For sure some regions will consider
#Combination #csDMARDs or
Switch to another
👇🤔
#sulfasalazine
#leflunomide
Depends on access, pt preference, disease activity/severity
#EULAR2025 @RheumNow @eular_org https://t.co/QDPcHhvQiV
Janet Pope Janetbirdope ( View Tweet)
Presenting our abstract on remote monitoring in rheumatology at #EULAR2025 @RBNHSFT @UniofReading @HenleyBSchool @RheumNow https://t.co/palWjtX3gM
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Leaky pipeline in rheumatology:
In a 23-country survey, women left hospital practice earlier—26% at trainee level vs 7% of men.
Top reasons?
🚫 Unfair promotion
🚫 Poor communication
🚫 No career path
Workplace equity still lags.
POS0407 @RheumNow #EULAR2025
Jiha Lee JihaRheum ( View Tweet)
RepurpSS-II RCT (n=46): LEF + HCQ significantly improved systemic disease activity (ESSDAI -4.13) vs PBO in primary #Sjögrens.
⭐️🌱STAR/CRESS response rates also favoured active treatment.
Safe, accessible, affordable option for active disease.
@RheumNow #EULAR2025 #LB0005
Mrinalini Dey DrMiniDey ( View Tweet)
Recommendations for RA management at #EULAR2025
- MTX [or other csDMARDs] and steroids still remain the first line- nothing beats that!
- ofcourse minimize steroids!
- rather than stopping meds at remission, reducing doses may be a better solution.
Not much changed.
@RheumNow https://t.co/NK5ejsgjWV
Bella Mehta bella_mehta ( View Tweet)
Proud to present the 1st #ARCH_ArLAR prospective interventional study #EULAR2025
Large awareness campaign ➡️
🔺️Proportion new referred CIRDs pts ⬆️ from 31 to 37%
🔺️Time 2 see a rheuma ⬇️ 14 to 10 mo
🔺️Time 2 diagnosis ⬇️ 18 to 12 mo
POS1310
@RheumNow
@ArLARheumatolog https://t.co/eKrRKHNXMZ
Nelly ZIADE 🍀 Nellziade ( View Tweet)
